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The six day subrenal capsule (SRC) assay was
developed by Bogden et al. (1978) as an in vivo
xenograft system that could be used to investigate
the effects of cytotoxic agents on a variety of
human tumours from xenografts established in
nude mice, and on primary surgical explants of
human tumours (Bogden et al., 1981). Initially, the
technique involved the use ofnude mice, but later it
was shown that it was possible to use normal
immunocompetent mice (Bogden et al., 1979). This,
of course, made the SRC very cost effective, and
the short time frame of the assay was seen as a
major advantage when compared to the time
required to grow xenografts subcutaneously in nude
mice.
Gastric adenocarcinoma is the fourth most
common malignancy in the UK. In general,
chemotherapy has made little impact on the disease,
and combination chemotherapy regimens will
usually produce objective tumour regression in only
30-45% of patients (Cunningham et al., 1984;
Schein et al., 1982). Nevertheless, those patients
who respond to chemotherapy undoubtedly benefit
in terms of survival, but the price is unnecessary
toxicity in those who do not respond (Cunningham
et al., 1985). We, therefore, felt that this was a
suitable tumour in which to study a predictive
chemotherapy system such as the SRC. Preliminary
information from Bogden's group suggested that it
should be feasible to grow primary surgical explants
from gastric cancer (Griffen et al., 1983), and we
therefore initiated a study to investigate the possible
role of the SRC as a chemopredictive test in gastric
cancer.
The technique used was similar to that described
by Bogden et al. (1978). Resected specimens were
placed immediately into tissue culture medium No.
199 and taken to the pathology department (all
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patients were operated on in GRI, therefore
transportation time for specimens was minimised
where a sample_ 1 cm3 was removed. This was
dissected into four 0.5ncm3 pieces and returned to
the tissue culture medium for transfer to the
laboratories. In the laboratory the tissue was
prepared for transplantation by dissection into
pieces 1 mm3 for which procedure a template
placed under a glass petri dish was used as a guide.
A specimen was retained for histological analysis.
The mice (C57BL/6 xDBA/2) F, hybrid, age 14-20
weeks were weighed, anaesthetised with diethyl
ether and an incision was made laterally in the
region of the left kidney, which was subsequently
exteriorised. An incision was made in the renal
capsule (Ziegler iridectomy knife with a 4mm
blade) and the tumour introduced using a trochar
(supplied by MacCarthy's Surgical Ltd, Dagenham,
UK). Two perpendicular diameters of tumour were
measured in situ using a Zeiss Stereoscopic
microscope with a micrometer scale such that 1
micrometer unit (MU) was equivalent to 0.1 mm.
After measurement the kidney was carefully re-sited
in the abdomen, and the incision was closed using a
stapler gun. Each control group had 5-8 mice and
each treatment group had 4-6 mice. All surgery
was carried out by one operator (DC) with
technical assistance from DFSMcM.
Six days later, the mice were killed, re-weighed
and the tumour re-measured in situ. An evaluable
assay was one in which the mean increase of the
sum of the two perpendicular diameters was
0.5MU (which is the same criterion as Bogden et
al., 1978). Thereafter, the tumour bearing kidney
was removed and placed in formol saline.
Chemotherapy was given on days 1, 3, 5 as
outlined in Table I. The drugs tested were those
employed in our current regimen for advanced
gastric cancer.
Sections, prepared from the mouse kidney and
implanted tumour, were stained with haematoxylin
and eosin. They were examined by one pathologist
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Table I Details ofchemotherapy
Injected dose Method of
Drug (mg kg'-) administration
Cisplatin 3.3 Subcutaneous
Epirubucin 6.6 Intravenous
Methotrexate 6.6 Subcutaneous
5-Flourouracil 80.0 Subcutaneous
without the knowledge of the group (control or
treated) of origin of the specimen. An Inflammation
Score was devised in which the degree of
inflammatory infiltrate was graded as follows:
none=0, mild= 1, moderate=2 and marked=3.
In addition to the tissue from surgical explants,
tumour was also obtained from a human xenograft
and an animal allograft for transplantation. These
were Wils tumour, which is a human lung
adenocarcinoma established in nude mice and
Walker 256 which is a rodent sarcoma grown in
Wistar rats.
Specimens of gastric adenocarcinoma were
obtained from 17 patients. Sixteen were from the
primary tumour and one was from a lymph node
metastasis. The specimens retained for histological
analysis all showed tumour. From the 17 gastric
tumours a total of 418 xenografts were transplanted
within the minimal possible time. Fourteen of the
17 tumours gave evaluable assays in the control
groups with a mean increase in the sum of the
tumour diameters of4.1 MU (range 1.6-10.5).
However, when the xenografts were examined
histologically tumour cells were present in only 26
(6%) and the remaining xenografts consisted of
fibrous tissue and a lymphocytic infiltrate. It should
be emphasised that although a small number of
xenografts contained tumour, this consisted of a
few acini or single tumour cells as shown in Figure
1. The extent to which the xenografts were infil-
trated by lymphocytes was significantly influenced
by the administration of cytotoxic drugs.
Xenografts from control groups invariably had a
pronounced lymphocytic infiltrate compared to
treated groups (Figure 2A, B). These findings were
reflected in the Inflammation Score which is
represented in Figure 3. Moreover, there was a
significantly positive correlation (P<0.001) between
the Inflammation Score and the increase in size of
the xenografts (Spearman's Rank Correlation). In
the case of one tumour, rather than giving the
treatment groups chemotherapy, the animals were
sacrificed on days 1, 3 and 5 and the tumours were
examined histologically. This revealed, as might be
expected, a progressive increase in the amount of
lymphocytic infiltrate over the period of the assay.
Also, there was no tumour seen in the transplanted
Figure 1 Section of the subrenal capsular xenograft 6
days after implantation. A single residual acinus of
gastric carcinoma is present. This finding was
exceptional, most animals showing no evidence of
tumour. (The figure appears refractile because of the
presence ofcollagen.) (H & E x 753)
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Figure 2 (A) Section of the xenograft from untreated
control animal 6 days after implantation. An intense
lymphocytic infiltrate is present, which extends into the
renal parenchyma; (B) Section of xenograft from a
5FU treated animal. In contrast to (A) there is no
significant inflammatory cell infiltrate. (H & E x 247)SUBRENAL CAPSULE ASSAY AND GASTRIC CANCER
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*P<0.001 *P<0.001 *P<0.01 *P<0.001
*Wilcoxon's signed rank test
Figure 3 Inflammation score for 418 xenografts derived from primary surgical explants.
tissue from day 1, despite the presence of abundant
tumour in the tissue examined histologically just
before transplantation. Moreover, in 3 cases a
portion of the tissue for transplantation was
retained and examined histologically; in all cases
there were viable tumour cells.
In both of the xenografts there was considerable
growth over the 6 day period. The mean increase in
tumour diameters for the Wils tumour and the
Walker 256 tumour was 11 MU and 65 MU
respectively. Representative xenograft for the
Walker tumour, on day 6, is shown in Figure 4A.
Histology confirmed that the increase in the size of
xenografts was due to tumour- (Figure 4B). There
was persistence of the lymphocytic infiltrate but in
view of the marked tumour growth, the contri-
bution of this to the increase in xenograft size was
probably negligible.
Although the original aim of this study was to
investigate the usefulness of the SRC assay as a
chemopredictive test for gastric cancer, it became
clear from the histological analysis of the
transplanted xenografts that this would not be
feasible. However, we have demonstrated a very
important size artefact related to the infiltration of
the xenograft by lymphocytes.
When Bogden et al. (1979) first introduced the
SRC assay, it was suggested that the short time
frame required for tumour growth would render
any immunological response to the implanted
tumour irrelevant. Subsequent experience was to
the contrary; Edelstain et al. (1983) have shown
that 6 days after transplantation, the tumour is
usually infiltrated by mouse 'response cells'.
Nevertheless, there was still debate about the
significance of this infiltrate, especially in terms of
its interference with assessment of the assay. Using
flow cytometry, Aamdal et al. (1984) demonstrated
that for human tumours established in nude mice
and subsequently transplanted under the SRC, that
the contribution of the lymphocytic infiltrate to the
overall volume of the xenograft was 15-25%. On
the basis of these results they concluded that the
inflammatory infiltrate was of little consequence to
the measurement ofxenograft growth.
For primary surgical explants from gastric cancer
we have shown conclusively that there is an
inherent defect within the SRC assay. Apparent
growth, as a result of lymphocytic infiltration
occurred within control xenografts which contained
no viable tumour cells whatsoever. It could be
argued that the 'take rate' of the assay could be
improved by only using tissue confirmed by frozen
section to have viable tumour cells. This may be
worth investigating. However, it should be
emphasised that in four of our 17 tumours the
presence of viable tumour cells was confirmed
histologically prior to transplantation and that
growth of tumour using the SRC technique was still
unsuccessful. Moreover, we have shown that the
extent to which infiltration occurred was influenced
by the administration of cytotoxic drugs, such that
tumours without infiltration were smaller than
those which did have infiltration. Clearly, using the
parameters of tumour measurement in this situation
is inadvisable, and might lead to the erroneous
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Figure 4 (A) Macroscopic appearance of the Walker 256 sarcoma 6 days after transplantation under the
renal capsule. (B) Section of Walker 256 tumour 6 days after subrenal capsular transplantation. Areas of
necrosis are present, but most of the tumour is viable. (H & E x 395)
assessment of a cytotoxic agent's activity against a
given tumour. Thus, for tumour derived from
primary surgical explants, histological validation of
the assay is essential. Levi et al. (1984) have
developed the SRC assay to include a histological
scoring system which encompasses both the extent
of tumour necrosis and the amount of lymphocytic
infiltration. This appears to be better and more
sensitive than tumour measurement alone, but
obviously has the disadvantage of making the SRC
assay more complex, and time consuming to
perform.
Our experience with the transplantation of
human and animal tumour xenografts under the
SRC has been limited to two tumour types.
Nevertheless, we have been impressed with the
reproducibility of the growth of these tumours
within the SRC system. Indeed, the scale of growth
was such that routine extensive histological analysis
should not be essential, and is unlikely to add to
simple tumour measurement. Moreover, in this
context the 'size artefact' related to lymphocytic
infiltration will be less relevant.
In conclusion, the growth of primary surgical
explants from gastric cancer under the SRC of mice
has, in our experience, not been possible. Also, in
general, histological validation of surgical explants
grown under SRC is advisable because of the size
artefact related to lymphocytic infiltration.
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